Familial exudative vitreoretinopathy

From WikiMD's WELLNESSPEDIA

A genetic disorder affecting the retina

Familial exudative vitreoretinopathy (FEVR) is a rare genetic disorder that affects the retina, the light-sensitive tissue at the back of the eye. This condition is characterized by incomplete development of the retinal blood vessels, leading to a range of vision problems.

Pathophysiology[edit]

FEVR is caused by mutations in genes that are involved in the development and maintenance of the retinal vasculature. These genes include NDP, FZD4, LRP5, TSPAN12, and others. The mutations lead to abnormal blood vessel growth and can result in retinal detachment, vitreous hemorrhage, and neovascularization.

Clinical Features[edit]

The clinical presentation of FEVR can vary widely, even among members of the same family. Common symptoms include:

Some individuals may be asymptomatic, while others may experience severe vision loss.

Diagnosis[edit]

Diagnosis of FEVR is based on clinical examination and imaging studies. Fluorescein angiography is often used to assess the retinal vasculature. Genetic testing can confirm the diagnosis by identifying mutations in the associated genes.

Genetics[edit]

FEVR is inherited in an autosomal dominant, autosomal recessive, or X-linked manner, depending on the gene involved. The most common form is autosomal dominant, which means a single copy of the mutated gene can cause the disorder.

Management[edit]

Management of FEVR focuses on monitoring and treating complications. This may include:

  • Regular ophthalmologic examinations
  • Laser photocoagulation to prevent retinal detachment
  • Vitrectomy surgery for severe cases
  • Genetic counseling for affected families

Prognosis[edit]

The prognosis for individuals with FEVR varies. Early detection and treatment of complications can help preserve vision. However, some individuals may experience progressive vision loss despite treatment.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.